Bank of America Securities analyst Geoff Meacham maintained a Buy rating on Bristol Myers (BMY – Research Report) yesterday and set a price target of $82.00. The company’s shares closed yesterday at $72.77.
Meacham covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Meacham has an average return of 5.1% and a 53.91% success rate on recommended stocks.
Currently, the analyst consensus on Bristol Myers is a Moderate Buy with an average price target of $84.29.
See Insiders’ Hot Stocks on TipRanks >>
BMY market cap is currently $151.4B and has a P/E ratio of 24.67.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Notable companies reporting before tomorrow’s open
- Prothena reports ‘positive’ topline Phase 1 study results for PRX005
- Bristol-Myers announces CHMP opinion recommending approval for Reblozyl
- Bristol-Myers’ Sotyktu recommended for approval in psoriasis by Europe’s CHMP